Serious Adverse Events in Randomized Psychosocial Treatment Studies: Safety or Arbitrary Edicts?

被引:34
|
作者
Petry, Nancy M. [1 ]
Roll, John M. [2 ]
Rounsaville, Bruce J. [3 ,4 ]
Ball, Samuel A. [3 ,4 ]
Stitzer, Maxine [5 ]
Peirce, Jessica M. [5 ]
Blaine, Jack [6 ]
Kirby, Kimberly C. [7 ,8 ]
McCarty, Dennis [9 ]
Carroll, Kathleen M. [3 ,4 ]
机构
[1] Univ Connecticut, Ctr Hlth, Dept Med, Calhoun Cardiol Ctr, Farmington, CT 06030 USA
[2] Washington State Univ, Intercollegiate Coll Nursing, Pullman, WA 99164 USA
[3] Yale Univ, Dept Psychiat, West Haven, CT 06520 USA
[4] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA
[5] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD 21218 USA
[6] Natl Inst Drug Abuse, Rockville, MD USA
[7] Treatment Res Inst, Philadelphia, PA USA
[8] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA
[9] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA
关键词
human subjects protection; serious adverse events; psychosocial treatments; good clinical practice; participant safety;
D O I
10.1037/a0013679
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Human subjects protection policies developed for pharmaceutical trials are now being widely applied to psychosocial intervention studies. This study examined occurrences of serious adverse events (SAEs) reported in multicenter psychosocial trials, of the National Institute on Drug Abuse Clinical Trials Network. Substance-abusing participants (N = 1.687) were randomized to standard care or standard care plus either contingency management or motivational enhancement. Twelve percent of participants experienced I or more SAEs during the 27.198 person-weeks of follow-up. Of the 260 SAEs recorded. none were judged by the data safety monitoring board to be study related, and there were no significant differences between experimental and control conditions in SAE incidence rates. These data underscore the need to reconsider the rationale behind, and appropriate methods for. monitoring safety during psychosocial therapy trials.
引用
收藏
页码:1076 / 1082
页数:7
相关论文
共 50 条
  • [1] Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
    Zhao, Bin
    Zhao, Hong
    Zhao, Jiaxin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [3] The safety of dual bronchodilation on cardiovascular serious adverse events in COPD
    Rogliani, Paola
    Ora, Josuel
    Matera, Maria Gabriella
    Cazzola, Mario
    Calzetta, Luigino
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (06) : 589 - 596
  • [4] Quantitative Methods for Safety Monitoring of Rare Serious Adverse Events
    Duke S.P.
    Kleoudis C.
    Polinkovsky M.
    Bennett D.
    Hill D.
    Lewis E.
    Pharmaceutical Medicine, 2017, 31 (2) : 113 - 118
  • [5] Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events
    Khanna, Reena
    Feagan, Brian G.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (06) : 987 - 997
  • [6] Serious adverse events following mRNA vaccination in randomized trials in adults
    Black, Steven
    Evans, Stephen
    VACCINE, 2023, 41 (23) : 3473 - 3474
  • [7] Safety of human albumin based on spontaneously reported serious adverse events
    von Hoegen, I
    Waller, C
    CRITICAL CARE MEDICINE, 2001, 29 (05) : 994 - 996
  • [8] Survey of serious adverse events and safety evaluation of oral anticancer drug treatment in Japan: A retrospective study
    Kawasumi, Kenji
    Kujirai, Azusa
    Matsui, Reiko
    Kawano, Yohei
    Yamaguchi, Masakazu
    Aoyama, Takao
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (01) : 1 - 9
  • [9] Regular treatment with formoterol for chronic asthma: serious adverse events
    Cates, Christopher J.
    Cates, Matthew J.
    Lasserson, Toby J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (04):
  • [10] Regular treatment with formoterol for chronic asthma: serious adverse events
    Cates, Christopher J.
    Cates, Matthew J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (04):